Physician profile
Alejandro Arzabala
NPI 1780894790
$4,086.58
in general payments reported to CMS, 2019-2025
18 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $2,097 · 2021: $416 · 2022: $380 · 2023: $293 · 2024: $93.27 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.69 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $2,212.86 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $695.17 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.42 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $151.43 | 2019-2023 | Uptravi |
| Sanofi-Aventis U.S. LLC | $96.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $93.36 | 2019-2022 | |
| Abiomed | $62.06 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $51.19 | 2021-2022 | |
| Philips North America LLC | $47.10 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $37.14 | 2019 | |
| Circassia INC. | $34.33 | 2019-2020 | |
| Insmed, INC. | $28.44 | 2021-2025 | Arikayce |
| Verona Pharma, INC. | $24.78 | 2025 | Ohtuvayre |
| Nabriva Therapeutics, Plc | $21.55 | 2020 | |
| Grifols USA, LLC | $18.38 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13.25 | 2021 | |
| Chiesi USA, INC. | $12.09 | 2019 | |
| Inogen, INC. | $4.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Arzabala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.